- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07433686
Saskatoon Berry Juice for Muscle Recovery
April 27, 2026 updated by: Phil Chilibeck, University of Saskatchewan
Effect of Short-term Saskatoon Berry Supplementation on Muscle Recovery
This study will evaluated the effect of Saskatoon berry juice on recovery from muscle-damaging exercise.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Saskatoon berries are high in polyphenols which are are anti-inflammatory and act as anti-oxidants.
They therefore have potential to protect muscle from damage induced by intense exercise.
Thirty participants will be randomized to receive Sasaktoon berries (375 ml) or placebo every day for 10 days.
On the seventh day participants will perform 6 sets of intense biceps curl exercise.
Isometric muscle strength, muscle swelling, and muscle soreness will be assessed before exercise, immediately after exercise, and 24, 48, and 72 hours after the exercise session.
We hypothesize the group receiving Saskatoon berries will have faster recovery of muscle strength, and reduction in swelling and muscle soreness after the exercise session.
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Philip Chilibeck, PhD
- Phone Number: 306-230-3849
- Email: phil.chilibeck@usask.ca
Study Locations
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 5B2
- Recruiting
- Physical Activity Complex, University of Saskatchewan
-
Contact:
- Philip Chilibeck, PhD
- Phone Number: 306-230-3849
- Email: phil.chilibeck@usask.ca
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male or female
- aged 18-35y
Exclusion Criteria:
- Conditions that might be affects by exercise as determined by the "Get Active Questionnaire"
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo (375 ml)
|
Placebo (375 ml)
|
|
Experimental: Saskatoon berry juice (375 ml)
Saskatoon berry juice
|
Saskatoon berries (375 ml)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in isometric biceps strength with a dynamometer (Nm)
Time Frame: 72 hours
|
72 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in biceps muscle thickness with ultrasound (cm)
Time Frame: 72 hours
|
72 hours
|
|
Change in muscle soreness with visual analog scale (score ranges from 0 to 10). No soreness = 0, maximal soreness = 10
Time Frame: 72 hours
|
72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 26, 2026
Primary Completion (Estimated)
August 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
February 19, 2026
First Submitted That Met QC Criteria
February 19, 2026
First Posted (Actual)
February 25, 2026
Study Record Updates
Last Update Posted (Actual)
April 28, 2026
Last Update Submitted That Met QC Criteria
April 27, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscle Damage
-
University of ThessalyCompletedAthletic Performance | Muscle Damage | Skeletal Muscle DamageGreece
-
PepsiCo Global R&DRecruitingMuscle Damage | MuscleUnited States
-
University of ExeterRecruiting
-
University of SaskatchewanCompleted
-
Riphah International UniversityCompleted
-
Northumbria UniversityNaturex SACompletedMuscle DamageUnited Kingdom
-
Bispebjerg HospitalLundbeck Foundation; The Danish Rheumatism Association; Team Denmark; Danish Ministry... and other collaboratorsCompletedMuscle DamageDenmark
-
University of SaskatchewanCompleted
-
University of New MexicoWithdrawn
-
University of SurreyCompletedMuscle DamageUnited Kingdom
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of